ArticlePloS one2012
A non-VH1-69 heterosubtypic neutralizing human monoclonal antibody protects mice against H1N1 and H5N1 viruses.
Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Article
- Broadly neutralizing monoclonal antibodies against influenza A viruses: current insights and future directions.Frontiers in microbiology · 2025Review
- Multiplexed Antibody Sequencing and Profiling of the Human Hemagglutinin-specific Memory B Cell Response following Influenza Vaccination.Journal of immunology (Baltimore, Md. : 1950) · 2024Article
- Dual oxidase 1 promotes antiviral innate immunity.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Influenza Virus and SARS-CoV-2 Vaccines.Journal of immunology (Baltimore, Md. : 1950) · 2021Review
- Polyreactive Broadly Neutralizing B cells Are Selected to Provide Defense against Pandemic Threat Influenza Viruses.Immunity · 2020Article
- Hemagglutinin stalk-based monoclonal antibody elicits broadly reactivity against group 1 influenza A virus.Virology journal · 2020Article
- Neutralizing Antibodies Targeting the Conserved Stem Region of Influenza Hemagglutinin.Vaccines · 2020Review
- Recombinant Influenza Vaccines: Saviors to Overcome Immunodominance.Frontiers in immunology · 2019Review
- A Broadly Reactive Human Anti-hemagglutinin Stem Monoclonal Antibody That Inhibits Influenza A Virus Particle Release.EBioMedicine · 2017Article
- Heterosubtypic protection conferred by the human monoclonal antibody PN-SIA28 against influenza A virus lethal infections in mice.Antimicrobial agents and chemotherapy · 2015Article
- Influenza virus antigenicity and broadly neutralizing epitopes.Current opinion in virology · 2015Review
- Prospects of HA-based universal influenza vaccine.BioMed research international · 2015Review
- Bispecific antibody generated with sortase and click chemistry has broad antiinfluenza virus activity.Proceedings of the National Academy of Sciences of the United States of America · 2014Article
- Alternative recognition of the conserved stem epitope in influenza A virus hemagglutinin by a VH3-30-encoded heterosubtypic antibody.Journal of virology · 2014Article
- A common solution to group 2 influenza virus neutralization.Proceedings of the National Academy of Sciences of the United States of America · 2014Article
- Article
- Multiantibody strategies for HIV.Clinical & developmental immunology · 2013Review
- Possible future monoclonal antibody (mAb)-based therapy against arbovirus infections.BioMed research international · 2013Review
- JC polyomavirus (JCV) and monoclonal antibodies: friends or potential foes?Clinical & developmental immunology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Influenza viruses are among the most important human pathogens and are responsible for annual epidemics and sporadic, potentially devastating pandemics. The humoral immune response plays an important role in the defense against these viruses, providing protection mainly by producing antibodies directed against the hemagglutinin (HA) glycoprotein. However, their high genetic variability allows the virus to evade the host immune response and the potential protection offered by seasonal vaccines. The emergence of resistance to antiviral drugs in recent years further limits the options available for the control of influenza. The development of alternative strategies for influenza prophylaxis and therapy is therefore urgently needed. In this study, we describe a human monoclonal antibody (PN-SIA49) that recognizes a highly conserved epitope located on the stem region of the HA and able to neutralize a broad spectrum of influenza viruses belonging to different subtypes (H1, H2 and H5). Furthermore, we describe its protective activity in mice after lethal challenge with H1N1 and H5N1 viruses suggesting a potential application in the treatment of influenza virus infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.